What is the MVista Antigen Assay?
The MVista antigen assay is a commercial enzyme immunoassay (EIA) manufactured by MiraVista Diagnostics that detects galactomannan antigens from endemic fungi—primarily Histoplasma capsulatum, but also Blastomyces dermatitidis and Coccidioides species—in urine and serum specimens for rapid diagnosis of active fungal infections.
Clinical Purpose and Performance
The MVista antigen test serves as a critical non-culture-based diagnostic tool for endemic mycoses, particularly when rapid diagnosis is essential for initiating antifungal therapy in severe infections. For histoplasmosis specifically, the assay demonstrates excellent diagnostic performance with overall sensitivity of 81.4% and specificity of 98.3% 1. Performance varies by specimen type: antigenemia shows slightly higher sensitivity (83.9%) compared to antigenuria (79.5%), though specificities are comparable 1.
Key Performance Characteristics:
- Positive likelihood ratio: 43.2
- Negative likelihood ratio: 0.18
- Odds ratio: 321 (95% CI, 118–875)
- Area under the curve: 0.98 1
This makes it an excellent discriminator between healthy and infected individuals.
Clinical Applications
Diagnostic Utility by Disease Type
For disseminated histoplasmosis, the MVista antigen assay performs optimally, as most validation studies focused on this presentation 1. In acute pulmonary histoplasmosis, sensitivity is lower (64-68%) when used alone, but combining urine and serum antigen testing increases sensitivity to 93%, and adding antibody testing further increases it to 96.3% 1.
For blastomycosis, the assay shows 92.9% sensitivity and 79.3% specificity in confirmed cases, covering both localized pulmonary and disseminated disease 1.
Quantitative Monitoring
Beyond diagnosis, the MVista assay provides quantitative results that serve multiple clinical purposes 1:
- Severity assessment: Antigen levels >16 pg/mL have 88% positive predictive value for moderate-to-severe histoplasmosis requiring inpatient amphotericin B therapy
- Treatment monitoring: Levels decrease with effective antifungal therapy
- Relapse prediction: Rising levels predict disease relapse
Critical Limitations
Cross-Reactivity Issues
The major clinical pitfall is significant cross-reactivity with other endemic mycoses 1. The Histoplasma antigen is detected in the majority of patients with:
- Blastomycosis
- Coccidioidomycosis
- Paracoccidioidomycosis
- Talaromycosis
This cross-reactivity necessitates correlation with clinical context, geographic exposure, and complementary testing to prevent misdiagnosis 1.
Availability Constraints
Testing is restricted to reference laboratories in the United States, which delays results and limits utility for rapid diagnosis in severe infections 1. This is particularly problematic in endemic areas outside the US, such as Latin America and Africa, where the disease burden is high but access is limited.
Newer Assay Formats
Recent developments include a lateral flow assay (LFA) version of the MVista Histoplasma antigen test, designed for resource-limited settings 2, 3. The LFA shows:
- Sensitivity: 78.8% (higher in proven cases at 93.2% and disseminated disease at 91.3%)
- Specificity: 99.3%
- High concordance with EIA (κ = 0.84)
The LFA requires minimal laboratory infrastructure and can be read manually or with an automated reader, making it suitable for point-of-care testing 2, 3.
Recommended Testing Strategy
Never order MVista antigen testing in isolation 1. The optimal approach combines:
- Antigen testing (urine AND serum for maximum sensitivity)
- Antibody/serology testing (though less sensitive in immunocompromised patients)
- Culture and direct visualization when feasible
- Clinical and epidemiologic data (geographic exposure, immune status)
This multi-test strategy is particularly critical given the cross-reactivity issues and the fact that no single test has sufficient sensitivity to rule out disease when used alone 1.